Myltenyi Biotech – New modules to expand processing capabilities of the CliniMACS Prodigy® Platform: electroporation and final formulation.
June 20, 2023
The CliniMACS Prodigy represents the next generation in automated cell processing. This device offers advanced integrated solutions to streamline cell processing workflows – from cell separation through cell culture to formulation of the final product. Two new modules expand the processing capabilities of the CliniMACS Prodigy® Platform
The CliniMACS ® Electroporator enables flexibility in large-scale transfection of various cell types. The electroporation step is integrated into the automated cell manufacturing workflow of the CliniMACS Prodigy. After washing and rebuffering on the CliniMACS Prodigy, cells are transferred to the CliniMACS Electroporator. The cell suspension is divided into smaller samples and mixed with transfection material such as nucleic acids. Electroporation of the divided sample takes place in the electroporation cuvette, which is a component of the single-use CliniMACS Electroporation Tubing Set. After electroporation, cells are transferred back to the CliniMACS Prodigy for downstream cell processing.
The CliniMACS Formulation Unit includes automated sampling of cells and automated and closed formulation to deliver fresh or frozen final cell products. Full end-to-end automation with the CliniMACS Formulation Unit avoids risky manual cell formation steps. Uninterrupted cell processing and final formulation guarantee safety for your cells and short cuts quality control procedures.